Recent Updates
Recently added Catalysts
VRTX Positive Sentiment

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

Tuesday, September 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vertex Pharmaceuticals has teamed up with champion skier Lindsey Vonn to promote JOURNAVX, a non-opioid medication approved for treating moderate-to-severe acute pain. This partnership aims to raise awareness about the first new class of pain medicine in over two decades. JOURNAVX was approved by the FDA in January 2025.

Market Sentiment Analysis

POSITIVE FACTORS

  • Partnership with Lindsey Vonn enhances awareness of JOURNAVX.
  • JOURNAVX is a new class of pain medicine approved by the FDA.
  • Offers a non-opioid treatment option for acute pain.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
1.9%
average across 14 past catalysts
Lead asset
VX-880
Phase 3 · Diabetes Mellitus, Type 1

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to over

Frequently Asked Questions

What is JOURNAVX?

JOURNAVX is a prescription non-opioid medicine for treating moderate-to-severe acute pain.

Who is partnering with Vertex Pharmaceuticals?

Vertex has partnered with world champion skier Lindsey Vonn.

When was JOURNAVX approved by the FDA?

JOURNAVX was approved by the FDA in January 2025.

What is the significance of JOURNAVX?

It represents the first new class of pain medicine in over 20 years.

ShareAdd on Google
Tags: VRTX Viatris Investor Conferences Healthcare Vertex Pharmaceuticals Lindsey Vonn JOURNAVX non-opioid medicine FDA approval
Last updated: Sep 15, 2026

Biotech snapshot

Cash runway
$13642M liquidity · $0M/mo burn
Low dilution risk
Lead asset
VX-880Phase 3
Diabetes Mellitus, Type 1 →

Catalyst track record

+13%
best trade around VRTX's most recent catalyst

Peak hindsight return over a 120-day window, across 14 tracked FDA/PDUFA catalysts for VRTX.

See every catalyst's timing & PoA →